RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) was upgraded by stock analysts at HC Wainwright to a "strong-buy" rating in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm currently has a $6.00 price target on the stock. HC Wainwright's target price points to a potential upside of 387.80% from the company's previous close.
RAPT Therapeutics Stock Performance
RAPT Therapeutics stock traded up $0.37 during midday trading on Thursday, reaching $1.23. The stock had a trading volume of 4,442,745 shares, compared to its average volume of 1,277,208. The stock's 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.16. RAPT Therapeutics has a twelve month low of $0.71 and a twelve month high of $4.60. The stock has a market capitalization of $162.72 million, a PE ratio of -0.44 and a beta of -0.04.
RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. Equities analysts predict that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On RAPT Therapeutics
Several institutional investors have recently bought and sold shares of RAPT. Picton Mahoney Asset Management raised its stake in shares of RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after acquiring an additional 14,697 shares during the period. JPMorgan Chase & Co. boosted its position in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after purchasing an additional 25,130 shares during the period. Simplicity Wealth LLC acquired a new stake in RAPT Therapeutics in the 1st quarter valued at $25,000. Barclays PLC raised its position in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $63,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.
About RAPT Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Read More
Before you consider RAPT Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RAPT Therapeutics wasn't on the list.
While RAPT Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
